1
|
Feliu V, Gomez-Roca C, Michelas M, Thébault N, Lauzéral-Vizcaino F, Salvioni A, Scandella L, Sarot E, Valle C, Balança CC, Scarlata CM, Delord JP, Ayyoub M, Devaud C. Distant antimetastatic effect of enterotropic colon cancer-derived α4β7 +CD8 + T cells. Sci Immunol 2023; 8:eadg8841. [PMID: 37289857 DOI: 10.1126/sciimmunol.adg8841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Accepted: 03/29/2023] [Indexed: 06/10/2023]
Abstract
Despite the high prognostic value of immune infiltrates in colorectal cancer (CRC), metastatic disease remains resistant to immunotherapy by immune checkpoint blockade (ICB). Here, we show, in metastatic CRC preclinical models, that orthotopically implanted primary colon tumors exert a colon-specific antimetastatic effect on distant hepatic lesions. Enterotropic α4β7 integrin-expressing neoantigen-specific CD8 T cells were key components of the antimetastatic effect. Accordingly, the presence of concomitant colon tumors improved control of liver lesions by anti-PD-L1 proof-of-concept immunotherapy and generated protective immune memory, whereas partial depletion of α4β7+ cells abrogated control of metastases. Last, in patients with metastatic CRC, response to ICB was associated with expression of α4β7 integrin in metastases and with circulating α4β7+ CD8 T cells. Our findings identify a systemic cancer immunosurveillance role for gut-primed tumor-specific α4β7+ CD8 T cells.
Collapse
Affiliation(s)
- Virginie Feliu
- Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
- Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Institut Claudius Regaud, Toulouse, France
| | - Carlos Gomez-Roca
- Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
- Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Institut Claudius Regaud, Toulouse, France
| | - Marie Michelas
- Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
- Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Institut Claudius Regaud, Toulouse, France
| | - Noémie Thébault
- Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
- Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Institut Claudius Regaud, Toulouse, France
| | - Françoise Lauzéral-Vizcaino
- Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Anna Salvioni
- Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
- Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Institut Claudius Regaud, Toulouse, France
| | - Lise Scandella
- Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Emeline Sarot
- Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Carine Valle
- Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Camille-Charlotte Balança
- Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
- Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Institut Claudius Regaud, Toulouse, France
| | - Clara-Maria Scarlata
- Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
- Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Institut Claudius Regaud, Toulouse, France
| | - Jean-Pierre Delord
- Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
- Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Institut Claudius Regaud, Toulouse, France
| | - Maha Ayyoub
- Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
- Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Institut Claudius Regaud, Toulouse, France
| | - Christel Devaud
- Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
- Institut Universitaire du Cancer de Toulouse (IUCT)-Oncopole, Institut Claudius Regaud, Toulouse, France
| |
Collapse
|
2
|
Martinez-Gomez C, Michelas M, Scarlata CM, Salvioni A, Gomez-Roca C, Sarradin V, Lauzéral-Vizcaino F, Féliu V, Dupret-Bories A, Ferron G, Sarini J, Devaud C, Delord JP, Balança CC, Martinez A, Ayyoub M. Circulating Exhausted PD-1+CD39+ Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade. Cancers (Basel) 2022; 14:cancers14153679. [PMID: 35954341 PMCID: PMC9367599 DOI: 10.3390/cancers14153679] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2022] [Revised: 07/22/2022] [Accepted: 07/26/2022] [Indexed: 01/21/2023] Open
Abstract
Simple Summary Not all cancer patients receiving immunotherapy by immune checkpoint blockade experience a clinical benefit. Our study was aimed at identifying biomarkers that could guide the selection of immunotherapy-responsive patients. Immunotherapy targets two major populations of lymphocytes: CD8 T cells, which directly kill tumor cells, and CD4 T cells, which provide help to CD8 T cells, the role of which in clinical responsiveness to immunotherapy has been less explored. We identified, in the blood of cancer patients, a population of CD4 T cells expressing inhibitory receptors targeted by immunotherapy. We showed that these cells were activated and proliferating, indicating their potential involvement in ongoing immune responses. Accordingly, we showed that they were specific for tumor antigens. In a prospective cohort, we showed that high proportions of these cells prior to therapy were associated with a response to immunotherapy. Abstract Tumor-infiltrating exhausted PD-1hiCD39+ tumor-antigen (Ag)-specific CD4 T cells contribute to the response to immune checkpoint blockade (ICB), but their circulating counterparts, which could represent accessible biomarkers, have not been assessed. Here, we analyzed circulating PD-1+CD39+ CD4 T cells and show that this population was present at higher proportions in cancer patients than in healthy individuals and was enriched in activated HLA-DR+ and ICOS+ and proliferating KI67+ cells, indicative of their involvement in ongoing immune responses. Among memory CD4 T cells, this population contained the lowest proportions of cells producing effector cytokines, suggesting they were exhausted. In patients with HPV-induced malignancies, the PD-1+CD39+ population contained high proportions of HPV Ag-specific T cells. In patients treated by ICB for HPV-induced tumors, the proportion of circulating PD-1+CD39+ CD4 T cells was predictive of the clinical response. Our results identify CD39 expression as a surrogate marker of circulating helper tumor-Ag-specific CD4 T cells.
Collapse
Affiliation(s)
- Carlos Martinez-Gomez
- Centre de Recherches en Cancérologie de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Université de Toulouse, 31037 Toulouse, France; (C.M.-G.); (M.M.); (C.-M.S.); (A.S.); (C.G.-R.); (V.S.); (F.L.-V.); (V.F.); (C.D.); (J.-P.D.); (C.-C.B.); (A.M.)
- Department of Surgery, IUCT-Oncopole, 31059 Toulouse, France; (A.D.-B.); (G.F.); (J.S.)
| | - Marie Michelas
- Centre de Recherches en Cancérologie de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Université de Toulouse, 31037 Toulouse, France; (C.M.-G.); (M.M.); (C.-M.S.); (A.S.); (C.G.-R.); (V.S.); (F.L.-V.); (V.F.); (C.D.); (J.-P.D.); (C.-C.B.); (A.M.)
| | - Clara-Maria Scarlata
- Centre de Recherches en Cancérologie de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Université de Toulouse, 31037 Toulouse, France; (C.M.-G.); (M.M.); (C.-M.S.); (A.S.); (C.G.-R.); (V.S.); (F.L.-V.); (V.F.); (C.D.); (J.-P.D.); (C.-C.B.); (A.M.)
- Immune Monitoring Core Facility, IUCT-Oncopole, 31059 Toulouse, France
| | - Anna Salvioni
- Centre de Recherches en Cancérologie de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Université de Toulouse, 31037 Toulouse, France; (C.M.-G.); (M.M.); (C.-M.S.); (A.S.); (C.G.-R.); (V.S.); (F.L.-V.); (V.F.); (C.D.); (J.-P.D.); (C.-C.B.); (A.M.)
| | - Carlos Gomez-Roca
- Centre de Recherches en Cancérologie de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Université de Toulouse, 31037 Toulouse, France; (C.M.-G.); (M.M.); (C.-M.S.); (A.S.); (C.G.-R.); (V.S.); (F.L.-V.); (V.F.); (C.D.); (J.-P.D.); (C.-C.B.); (A.M.)
- Department of Medical Oncology, IUCT-Oncopole, 31059 Toulouse, France
| | - Victor Sarradin
- Centre de Recherches en Cancérologie de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Université de Toulouse, 31037 Toulouse, France; (C.M.-G.); (M.M.); (C.-M.S.); (A.S.); (C.G.-R.); (V.S.); (F.L.-V.); (V.F.); (C.D.); (J.-P.D.); (C.-C.B.); (A.M.)
- Department of Medical Oncology, IUCT-Oncopole, 31059 Toulouse, France
| | - Françoise Lauzéral-Vizcaino
- Centre de Recherches en Cancérologie de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Université de Toulouse, 31037 Toulouse, France; (C.M.-G.); (M.M.); (C.-M.S.); (A.S.); (C.G.-R.); (V.S.); (F.L.-V.); (V.F.); (C.D.); (J.-P.D.); (C.-C.B.); (A.M.)
| | - Virginie Féliu
- Centre de Recherches en Cancérologie de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Université de Toulouse, 31037 Toulouse, France; (C.M.-G.); (M.M.); (C.-M.S.); (A.S.); (C.G.-R.); (V.S.); (F.L.-V.); (V.F.); (C.D.); (J.-P.D.); (C.-C.B.); (A.M.)
| | - Agnès Dupret-Bories
- Department of Surgery, IUCT-Oncopole, 31059 Toulouse, France; (A.D.-B.); (G.F.); (J.S.)
| | - Gwénaël Ferron
- Department of Surgery, IUCT-Oncopole, 31059 Toulouse, France; (A.D.-B.); (G.F.); (J.S.)
| | - Jérôme Sarini
- Department of Surgery, IUCT-Oncopole, 31059 Toulouse, France; (A.D.-B.); (G.F.); (J.S.)
| | - Christel Devaud
- Centre de Recherches en Cancérologie de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Université de Toulouse, 31037 Toulouse, France; (C.M.-G.); (M.M.); (C.-M.S.); (A.S.); (C.G.-R.); (V.S.); (F.L.-V.); (V.F.); (C.D.); (J.-P.D.); (C.-C.B.); (A.M.)
| | - Jean-Pierre Delord
- Centre de Recherches en Cancérologie de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Université de Toulouse, 31037 Toulouse, France; (C.M.-G.); (M.M.); (C.-M.S.); (A.S.); (C.G.-R.); (V.S.); (F.L.-V.); (V.F.); (C.D.); (J.-P.D.); (C.-C.B.); (A.M.)
- Department of Medical Oncology, IUCT-Oncopole, 31059 Toulouse, France
| | - Camille-Charlotte Balança
- Centre de Recherches en Cancérologie de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Université de Toulouse, 31037 Toulouse, France; (C.M.-G.); (M.M.); (C.-M.S.); (A.S.); (C.G.-R.); (V.S.); (F.L.-V.); (V.F.); (C.D.); (J.-P.D.); (C.-C.B.); (A.M.)
| | - Alejandra Martinez
- Centre de Recherches en Cancérologie de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Université de Toulouse, 31037 Toulouse, France; (C.M.-G.); (M.M.); (C.-M.S.); (A.S.); (C.G.-R.); (V.S.); (F.L.-V.); (V.F.); (C.D.); (J.-P.D.); (C.-C.B.); (A.M.)
- Department of Surgery, IUCT-Oncopole, 31059 Toulouse, France; (A.D.-B.); (G.F.); (J.S.)
| | - Maha Ayyoub
- Centre de Recherches en Cancérologie de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Université de Toulouse, 31037 Toulouse, France; (C.M.-G.); (M.M.); (C.-M.S.); (A.S.); (C.G.-R.); (V.S.); (F.L.-V.); (V.F.); (C.D.); (J.-P.D.); (C.-C.B.); (A.M.)
- Immune Monitoring Core Facility, IUCT-Oncopole, 31059 Toulouse, France
- Correspondence: ; Tel.: +33-(0)582741687
| |
Collapse
|
3
|
Balança CC, Salvioni A, Scarlata CM, Michelas M, Martinez-Gomez C, Gomez-Roca C, Sarradin V, Tosolini M, Valle C, Pont F, Ferron G, Gladieff L, Vergez S, Dupret-Bories A, Mery E, Rochaix P, Fournié JJ, Delord JP, Devaud C, Martinez A, Ayyoub M. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells. JCI Insight 2021; 6:142513. [PMID: 33332284 PMCID: PMC7934837 DOI: 10.1172/jci.insight.142513] [Citation(s) in RCA: 52] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Accepted: 12/09/2020] [Indexed: 01/03/2023] Open
Abstract
Tumor antigen-specific CD4 T cells accumulate at tumor sites, evoking their involvement in antitumor effector functions in situ. Contrary to CD8 cytotoxic T lymphocyte exhaustion, that of CD4 T cells remains poorly appreciated. Here, using phenotypic, transcriptomic, and functional approaches, we characterized CD4 T cell exhaustion in patients with head and neck, cervical, and ovarian cancer. We identified a CD4 tumor-infiltrating lymphocyte (TIL) population, defined by high PD-1 and CD39 expression, which contained high proportions of cytokine-producing cells, although the quantity of cytokines produced by these cells was low, evoking an exhausted state. Terminal exhaustion of CD4 TILs was instated regardless of TIM-3 expression, suggesting divergence with CD8 T cell exhaustion. scRNA-Seq and further phenotypic analyses uncovered similarities with the CD8 T cell exhaustion program. In particular, PD-1hiCD39+ CD4 TILs expressed the exhaustion transcription factor TOX and the chemokine CXCL13 and were tumor antigen specific. In vitro, PD-1 blockade enhanced CD4 TIL activation, as evidenced by increased CD154 expression and cytokine secretion, leading to improved dendritic cell maturation and consequently higher tumor-specific CD8 T cell proliferation. Our data identify exhausted CD4 TILs as players in responsiveness to immune checkpoint blockade.
Collapse
Affiliation(s)
| | - Anna Salvioni
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France
| | - Clara-Maria Scarlata
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.,Immune Monitoring Core Facility
| | - Marie Michelas
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France
| | - Carlos Martinez-Gomez
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.,Department of Surgery, and
| | - Carlos Gomez-Roca
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.,Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Victor Sarradin
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.,Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Marie Tosolini
- Technological Pole and Bioinformatic Platform, Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France
| | - Carine Valle
- Technological Pole and Bioinformatic Platform, Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France
| | - Frédéric Pont
- Technological Pole and Bioinformatic Platform, Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France
| | | | - Laurence Gladieff
- Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Sébastien Vergez
- Department of Surgery, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse, Toulouse, France.,Université Toulouse III Paul Sabatier, Toulouse, France
| | | | - Eliane Mery
- Department of Pathology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Philippe Rochaix
- Department of Pathology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | | | - Jean-Pierre Delord
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.,Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.,Université Toulouse III Paul Sabatier, Toulouse, France
| | - Christel Devaud
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France
| | - Alejandra Martinez
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.,Department of Surgery, and
| | - Maha Ayyoub
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.,Immune Monitoring Core Facility.,Université Toulouse III Paul Sabatier, Toulouse, France
| |
Collapse
|
4
|
Laplagne C, Meddour S, Figarol S, Michelas M, Calvayrac O, Favre G, Laurent C, Fournié JJ, Cabantous S, Poupot M. Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer. Front Immunol 2020; 11:1396. [PMID: 32733462 PMCID: PMC7358576 DOI: 10.3389/fimmu.2020.01396] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Accepted: 06/01/2020] [Indexed: 11/25/2022] Open
Abstract
Vγ9Vδ2 T cells are known to be efficient anti-tumor effectors activated through phosphoantigens (PAg) that are naturally expressed by tumor cells or induced by amino bisphosphonates treatment. This PAg-activation which is TCR and butyrophilin BTN3A dependent can be modulated by NKG2D ligands, immune checkpoint ligands, adhesion molecules, and costimulatory molecules. This could explain the immune-resistance observed in certain clinical trials based on Vγ9Vδ2 T cells therapies. In NSCLC, encouraging responses were obtained with zoledronate administrations for 50% of patients. According to the in vivo results, we showed that the in vitro Vγ9Vδ2 T cell reactivity depends on the NSCLC cell line considered. If the PAg-pretreated KRAS mutated A549 is highly recognized and killed by Vγ9Vδ2 T cells, the EGFR mutated PC9 remains resistant to these killers despite a pre-treatment either with zoledronate or with exogenous BrHPP. The immune resistance of PC9 was shown not to be due to immune checkpoint ligands able to counterbalance NKG2D ligands or adhesion molecules such as ICAM-1 highly expressed by PC9. RHOB has been shown to be involved in the Vγ9Vδ2 TCR signaling against these NSCLC cell lines, in this study we therefore focused on its intracellular behavior. In comparison to a uniform distribution of RHOB in endosomes and at the plasma membrane in A549, the presence of large endosomal clusters of RHOB was visualized by a split-GFP system, suggesting that RHOB rerouting in the PC9 tumor cell could impair the reactivity of the immune response.
Collapse
Affiliation(s)
- Chloé Laplagne
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France
| | - Sarah Meddour
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France
| | - Sarah Figarol
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France
| | - Marie Michelas
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France
| | - Olivier Calvayrac
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France
| | - Gilles Favre
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,IUCT-O, Toulouse, France
| | - Camille Laurent
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,IUCT-O, Toulouse, France
| | - Jean-Jacques Fournié
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France
| | - Stéphanie Cabantous
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France
| | - Mary Poupot
- Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France
| |
Collapse
|
5
|
Balança CC, Scarlata CM, Michelas M, Devaud C, Sarradin V, Franchet C, Martinez Gomez C, Gomez-Roca C, Tosolini M, Heaugwane D, Lauzéral-Vizcaino F, Mir-Mesnier L, Féliu V, Valle C, Pont F, Ferron G, Gladieff L, Motton S, Tanguy Le Gac Y, Dupret-Bories A, Sarini J, Vairel B, Illac C, Siegfried-Vergnon A, Mery E, Fournié JJ, Vergez S, Delord JP, Rochaix P, Martinez A, Ayyoub M. Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies. Cancer Immunol Res 2020; 8:869-882. [PMID: 32295784 DOI: 10.1158/2326-6066.cir-19-0855] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2019] [Revised: 02/04/2020] [Accepted: 04/09/2020] [Indexed: 11/16/2022]
Abstract
Although understanding of T-cell exhaustion is widely based on mouse models, its analysis in patients with cancer could provide clues indicating tumor sensitivity to immune checkpoint blockade (ICB). Data suggest a role for costimulatory pathways, particularly CD28, in exhausted T-cell responsiveness to PD-1/PD-L1 blockade. Here, we used single-cell transcriptomic, phenotypic, and functional approaches to dissect the relation between CD8+ T-cell exhaustion, CD28 costimulation, and tumor specificity in head and neck, cervical, and ovarian cancers. We found that memory tumor-specific CD8+ T cells, but not bystander cells, sequentially express immune checkpoints once they infiltrate tumors, leading, in situ, to a functionally exhausted population. Exhausted T cells were nonetheless endowed with effector and tumor residency potential but exhibited loss of the costimulatory receptor CD28 in comparison with their circulating memory counterparts. Accordingly, PD-1 inhibition improved proliferation of circulating tumor-specific CD8+ T cells and reversed functional exhaustion of specific T cells at tumor sites. In agreement with their tumor specificity, high infiltration of tumors by exhausted cells was predictive of response to therapy and survival in ICB-treated patients with head and neck cancer. Our results showed that PD-1 blockade-mediated proliferation/reinvigoration of circulating memory T cells and local reversion of exhaustion occur concurrently to control tumors.
Collapse
Affiliation(s)
| | | | - Marie Michelas
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France
| | - Christel Devaud
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France
| | - Victor Sarradin
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.,Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Camille Franchet
- Department of Pathology, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse, Toulouse, France.,Université Toulouse III Paul Sabatier, Toulouse, France
| | - Carlos Martinez Gomez
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.,Department of Surgery, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Carlos Gomez-Roca
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.,Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Marie Tosolini
- Technological Pole and Bioinformatic Platform, Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France
| | - Diana Heaugwane
- Department of Pathology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Françoise Lauzéral-Vizcaino
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.,Université Toulouse III Paul Sabatier, Toulouse, France
| | - Lucile Mir-Mesnier
- Immune Monitoring Core Facility, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Virginie Féliu
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France
| | - Carine Valle
- Technological Pole and Bioinformatic Platform, Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France
| | - Frédéric Pont
- Technological Pole and Bioinformatic Platform, Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France
| | - Gwénaël Ferron
- Department of Surgery, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Laurence Gladieff
- Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Stéphanie Motton
- Department of Surgery, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Yann Tanguy Le Gac
- Department of Surgery, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Agnès Dupret-Bories
- Department of Surgery, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Jérôme Sarini
- Department of Surgery, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Benjamin Vairel
- Department of Surgery, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Claire Illac
- Department of Pathology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Aurore Siegfried-Vergnon
- Department of Pathology, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Eliane Mery
- Department of Pathology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | | | - Sébastien Vergez
- Université Toulouse III Paul Sabatier, Toulouse, France.,Department of Surgery, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Jean-Pierre Delord
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.,Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France.,Université Toulouse III Paul Sabatier, Toulouse, France
| | - Philippe Rochaix
- Department of Pathology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Alejandra Martinez
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France.,Department of Surgery, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Maha Ayyoub
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France. .,Université Toulouse III Paul Sabatier, Toulouse, France.,Immune Monitoring Core Facility, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| |
Collapse
|
6
|
Franchini DM, Michelas M, Lanvin O, Poupot M, Fournié JJ. BTN3A1-antibodies and phosphoantigens: TCRVγ9Vδ2 "see" the difference. Eur J Immunol 2017; 47:954-957. [PMID: 28597565 DOI: 10.1002/eji.201747058] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2017] [Revised: 04/21/2017] [Accepted: 04/26/2017] [Indexed: 11/11/2022]
Abstract
Human blood γδ T lymphocytes express TCRVγ9Vδ2 and respond to nonpeptide phosphoantigens (PAgs) by a mysterious mechanism involving the BTN3A1 (CD277) molecule . BTN3A1 is a butyrophilin-like protein related to CD80, PD-L1, and MHC, and is either a presenting or a co-stimulatory molecule for PAgs. Although the precise roles and molecular interactions with the TCRVγ9Vδ2 are currently not determined, it is commonly thought that all TCRVγ9Vδ2 lymphocytes 'see' PAg and BTN3A1 together, presumably in a single molecular recognition event. But whether this recognition event could be reproduced in a simplified model was not addressed in previous studies. In this issue, Starick et al. (Eur. J. Immunol. 2017. 47: 982-992) compared the response of three TCRVγ9Vδ2 pairs of murine and human cell transfectants to PAg and anti-BTN3A1 antibodies using IL-2 release as a readout. The authors found that although the two murine transfectants responded similarly to either stimuli, one murine TCRVγ9Vδ2 transfectant reacted to PAgs but not to anti-BTN3A1 (mAb 20.1). Human transductants behave in a similar fashion, demonstrating that TCRVγ9Vδ2 lymphocytes differentiate PAg and BTN3A1 signals, while species of the transductants unmask this differential sensitivity. Indeed, understanding the puzzling mode of antigen recognition by γδ T lymphocytes will be essential for developing γδ T-cell-based immunotherapies, and the authors of this study now demonstrate that TCRVγ9Vδ2 lymphocytes are able to differentiate the PAg and BTN3A1 stimuli.
Collapse
Affiliation(s)
- Don-Marc Franchini
- Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR
| | - Marie Michelas
- Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR
| | - Olivia Lanvin
- Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR
| | - Mary Poupot
- Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR
| | - Jean Jacques Fournié
- Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,ERL 5294 CNRS, Toulouse, France.,Programme Hospitalo-Universitaire en Cancérologie CAPTOR
| |
Collapse
|